Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.
Status:
Completed
Trial end date:
2013-11-11
Target enrollment:
Participant gender:
Summary
This study is to define the pharmacokinetics and to evaluate the safety of BAY73-4506, 160 mg
once daily administered orally as a single agent in Japanese patients with advanced solid
tumors.